Compare Neurocrine Biosciences Inc (NBIX) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Teladoc Health Inc — how do they compare? Neurocrine Biosciences Inc trades at $143.3 (market cap $14.36B), while Teladoc Health Inc trades at $5.73 (market cap $1.01B). The key difference: Neurocrine Biosciences Inc is far larger — about 14.2× Teladoc Health Inc's market cap, and Teladoc Health Inc is more actively traded (4,668,477 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Teladoc Health Inc for 39 Days on average.
| NBIX | TDOC | |
|---|---|---|
Market Cap | $14.36B | $1.01B |
Volume | 1,237,180 | 4,668,477 |
Sector | Health | Health |
52-Week High | $185.50 | $9.72 |
52-Week Low | $123.10 | $4.47 |
Typical Hold Time | 23 Days | 39 Days |
Enterprise Value | $14.37B | $1.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Teladoc Health (TDOC) trades at $5.67, showing modest daily gains but remains near multi-year lows with a bearish technical outlook. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net margin in 2026. Recent management changes include the appointment of a new CFO, while analyst sentiment remains cautious despite a consensus price target of $8.83 representing 56% upside potential.
TDOC presents a high-risk opportunity with significant upside potential if the company can achieve profitability turnaround. The stock trades at discounted valuations (P/S 0.4x, P/B 0.77x) but faces execution risks from ongoing losses, BetterHelp segment challenges, and potential legal investigations. Free cash flow generation and integrated care growth provide stabilization, though sustained profitability remains the key catalyst needed for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
